Aspire Biopharma Holdings (ASBP) Profit After Tax (2021 - 2026)

Aspire Biopharma Holdings (ASBP) has reported Profit After Tax for 6 consecutive years, with -$1.3 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Profit After Tax rose 35.99% year-over-year to -$1.3 million in Q2 2026; TTM through Jun 2026 was -$11.0 million, a 41.55% increase from a year earlier, with the FY2025 full-year figure at -$24.5 million, down 1768.95% from the prior year.
• Profit After Tax was -$1.3 million for Q2 2026 at Aspire Biopharma Holdings, up from -$3.2 million in the prior quarter.
• Over five years, Profit After Tax peaked at $2.9 million in Q1 2023 and troughed at -$15.9 million in Q1 2025.
• A 5-year average of -$1.2 million and a median of -$183591.0 in 2023 frame the typical range for Profit After Tax.
• Across the five-year window, Profit After Tax surged 295484.64% in 2022 and tumbled 6801.9% in 2025, its largest moves.
• Over 5 years, Profit After Tax stood at $2.2 million in 2022, then sank by 106.77% to -$150913.0 in 2023, then sank by 407.39% to -$765710.0 in 2024, then plunged by 514.82% to -$4.7 million in 2025, then surged by 73.06% to -$1.3 million in 2026.
• The last three Profit After Tax figures came in at -$1.3 million (Q2 2026), -$3.2 million (Q1 2026), and -$4.7 million (Q4 2025), per Business Quant data.